Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Xinglei Chai, PhD, Cynthia Z. Qi, MBA, Eric Q Wu

Blood (2019) 134 (Supplement_1): 3419.

https://doi.org/10.1182/blood-2019-129070

Published: 2019

Journal Articles

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Cynthia Z. Qi, MBA, Xinglei Chai, PhD, Eric Q Wu

Blood (2019) 134 (Supplement_1): 4723.

https://doi.org/10.1182/blood-2019-129215

Published: 2019

Journal Articles

Cost Effectiveness of Novel Agents in the Treatment of Multiple Myeloma: A Systematic Review

Sarah Perry, MD MSc, Sylvia McCulloch, MD MSc

Blood (2019) 134 (Supplement_1): 4738.

https://doi.org/10.1182/blood-2019-125454

Published: 2019

Journal Articles

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Nanxin Li, Koo Wilson, Marc Botteman, MS, MA, Daniel Nicoloso, Sangeeta Krishnan, PharmD, Jun Su, MD

Blood (2018) 132 (Supplement 1): 3520.

https://doi.org/10.1182/blood-2018-99-114993

Published: 2018

Journal Articles

Health Care Utilization and Costs Among Patients with Chronic Myeloid Leukemia Using Tyrosine Kinase Inhibitors

Joanna C Huang, PharmD, Sudeep Karve, PhD, Sanchita Porwal, BS, Kushan Thakkar, MS, Thomas Marshall, PharmD, MS, Tanja Rosenberg, MD

Blood (2018) 132 (Supplement 1): 3537.

https://doi.org/10.1182/blood-2018-99-113809

Published: 2018

Journal Articles

Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States

Anuraag Kansal, PhD, Odette Reifsnider, Lora Todorova, Anna Coughlan, Kathleen F. Villa

Blood (2018) 132 (Supplement 1): 5837.

https://doi.org/10.1182/blood-2018-99-112252

Published: 2018

Journal Articles

Impact of Treatment Free Remission (TFR) with Nilotinib in 2 nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment

Andre Abdo, MD, Carla Maria Boquimpani, MD, Douglas Vivona, PhD, Viviane Silveira Leite, BSC, Alisson L. Matsuo, PhD, Vanessa Teich, BSC, Israel Bendit, MD PhD, Eduardo Magalhães Rego, MD PhD, Vanderson Rocha, MD PhD

Blood (2018) 132 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2018-99-119200

Published: 2018

Journal Articles

The Impact of Chronic Myeloid Leukemia Therapy Management on the Oncology Care Model

Elias J. Jabbour, MD, Martin F Mendiola, MD MPH, Melissa Lingohr-Smith, PhD, Brandy Menges, PhD, Jay Lin, PhD MBA, Dinara Makenbaeva, MD MBA

Blood (2018) 132 (Supplement 1): 2265.

https://doi.org/10.1182/blood-2018-99-112484

Published: 2018

Journal Articles

US Economic Impact of Recombinant FVIII Vs Plasma-Derived FVIII/VWF in Previously Untreated Hemophilia a Patients

Robert F. Sidonio, M. Chris Runken, Ken O'Day, Kellie Meyer, Jeffrey Spears

Blood (2017) 130 (Supplement 1): 2088.

https://doi.org/10.1182/blood.V130.Suppl_1.2088.2088

Published: 2017

Journal Articles

Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

Gabriel Tremblay, DBA, MSc, BS, Menaka Bhor, PhD, Anuja Roy, PhD, Brian Elliott, MD, Mike Dolph, MSc BHSc, Anna Forsythe, PharmD, MSc, MBA, Andrew Briggs, DPhil

Blood (2017) 130 (Supplement 1): 2146.

https://doi.org/10.1182/blood.V130.Suppl_1.2146.2146

Published: 2017

Journal Articles

Economic Model Shows That Guideline Recommended Testing of Patients with Early Symptoms of Myeloma Results in Improved Patient Outcomes and Decreased Hospital Costs

Elizabeth Wu, Ivar S Jensen, MBA, Philip Cyr, MPH, Harold Kisner

Blood (2017) 130 (Supplement 1): 4698.

https://doi.org/10.1182/blood.V130.Suppl_1.4698.4698

Published: 2017

Journal Articles

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Gili Kenet, MD, Abiola Oladapo, PhD BPharm, Josh Epstein, PhD, Thompson Christin, PhD, Aaron Novack, Diane J. Nugent, MD

Blood (2017) 130 (Supplement 1): 4632.

https://doi.org/10.1182/blood.V130.Suppl_1.4632.4632

Published: 2017

Journal Articles

Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)

Anuraag Kansal, Mark Du, Oscar Herrera-Restrepo, Robert Leipold, Robert J. Ryan, Arthur C. Louie, Karen Chung

Blood (2017) 130 (Supplement 1): 4674.

https://doi.org/10.1182/blood.V130.Suppl_1.4674.4674

Published: 2017

Journal Articles

Economic Modeling of the Potential Impact of Chronic Myeloid Leukemia (CML) Monitoring on Healthcare Costs

Elias J. Jabbour, MD, Lisa Siegartel, MPH, Jay Lin, PhD MBA, Melissa Lingohr-Smith, PhD, Brandy Menges, PhD, Dinara Makenbaeva, MD MBA

Blood (2017) 130 (Supplement 1): 3378.

https://doi.org/10.1182/blood.V130.Suppl_1.3378.3378

Published: 2017

Journal Articles

Health Utility during the First Two Years of Treatment of Hematological Malignancies

Sonya Cressman, PhD, Mary Lynn Savoie, MD FRCPC, Stephen Couban, MD, Emily McPherson, Alexa Evans, Stuart Peacock

Blood (2016) 128 (22): 3608.

https://doi.org/10.1182/blood.V128.22.3608.3608

Published: 2016

Journal Articles

Impact of Dose-Difference in Comparator Arms Among Clinical Trials on Treatment Effect Size in a Network Meta-Analysis: A Case of First-Line Therapies in Chronic Lymphocytic Leukemia (CLL)

Mkaya Mwamburi, PhD MD MA, Vasudha Bal, MSc, MBA, Teresa Cascella, MD, Anshul Shah, B.Pharm, MS, Merena Nanavaty, B. Pharm, MS, Smeet Gala, B.Tech, MS

Blood (2016) 128 (22): 5593.

https://doi.org/10.1182/blood.V128.22.5593.5593

Published: 2016

Journal Articles

A Multivariate Clinical and Economic Model for Predicting Risk-Based Costs of Care for Acute Leukemia (AL) Patients (Pts) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Joseph C. Alvarnas, MD, Guido Marcucci, MD, Ann Vanderplas, MS, Eileen P. Smith, MD, Joyce L. Murata-Collins, PhD, Alexandra M. Levine, MD, Joyce Niland, MD, Joycelynne Palmer, PhD, Tsai Ni-Chun, Rebecca Ottesen, Michael Rabin, Zara Dzagikian, Shery Azimi, Joseph Rosenthal, MD MS, Harlan Levine, MD, Stephen J. Forman, MD

Blood (2016) 128 (22): 3547.

https://doi.org/10.1182/blood.V128.22.3547.3547

Published: 2016

Journal Articles

Cost Differences of Same-Day Vs Next-Day Use of Pegfilgrastim

Xiaoyan Li, PhD, Xinke Zhang, MS, Junji Lin, PhD, Kelly Fust, MS, Jacob Garcia, MD

Blood (2015) 126 (23): 5566.

https://doi.org/10.1182/blood.V126.23.5566.5566

Published: 2015

Journal Articles

A Model Estimating Indirect Costs of Premature Death Associated with Severe Hepatic Veno-Occlusive Disease (sVOD) Among Hematopoietic Stem Cell Transplant (HSCT) Patients in the United States (U.S.)

Tiffany P. Quock, PhD MS, Zheng-Yi Zhou, PhD, Byran Dai, MS, Wenxi Tang, MS, Kathleen F. Villa, MS

Blood (2015) 126 (23): 3273.

https://doi.org/10.1182/blood.V126.23.3273.3273

Published: 2015

Journal Articles

Potential Economic Consequences of Genetic Mutations and Restricted Access to Tyrosine Kinase Inhibitor Treatments Among Patients with Chronic Myelogenous Leukemia in the USA

Elias Jabbour, MD, Makenbaeva Dinara, MD MBA, Lingohr-Smith Melissa, PhD, Lin Jay, PhD MBA

Blood (2014) 124 (21): 2645.

https://doi.org/10.1182/blood.V124.21.2645.2645

Published: 2014

NARROW

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Cost Effectiveness of Novel Agents in the Treatment of Multiple Myeloma: A Systematic Review

Economic Impact of Immune Tolerance Induction (ITI) with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Compared to Conventional Recombinant Factor VIII (rFVIII)

Health Care Utilization and Costs Among Patients with Chronic Myeloid Leukemia Using Tyrosine Kinase Inhibitors

Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States

Impact of Treatment Free Remission (TFR) with Nilotinib in 2 nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment

The Impact of Chronic Myeloid Leukemia Therapy Management on the Oncology Care Model

US Economic Impact of Recombinant FVIII Vs Plasma-Derived FVIII/VWF in Previously Untreated Hemophilia a Patients

Cost-Consequence Model Comparing Eltrombopag and Romiplostim for Pediatric Patients with Previously-Treated Chronic Immune Thrombocytopenia

Economic Model Shows That Guideline Recommended Testing of Patients with Early Symptoms of Myeloma Results in Improved Patient Outcomes and Decreased Hospital Costs

Estimating the Cost Savings and Cost Effectiveness of Low Dose Immune Tolerance Induction (ITI) Therapy with Bypassing Agent Prophylaxis Compared to High Dose ITI and Low Dose ITI

Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)

Economic Modeling of the Potential Impact of Chronic Myeloid Leukemia (CML) Monitoring on Healthcare Costs

Health Utility during the First Two Years of Treatment of Hematological Malignancies

Impact of Dose-Difference in Comparator Arms Among Clinical Trials on Treatment Effect Size in a Network Meta-Analysis: A Case of First-Line Therapies in Chronic Lymphocytic Leukemia (CLL)

A Multivariate Clinical and Economic Model for Predicting Risk-Based Costs of Care for Acute Leukemia (AL) Patients (Pts) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

Cost Differences of Same-Day Vs Next-Day Use of Pegfilgrastim

A Model Estimating Indirect Costs of Premature Death Associated with Severe Hepatic Veno-Occlusive Disease (sVOD) Among Hematopoietic Stem Cell Transplant (HSCT) Patients in the United States (U.S.)

Potential Economic Consequences of Genetic Mutations and Restricted Access to Tyrosine Kinase Inhibitor Treatments Among Patients with Chronic Myelogenous Leukemia in the USA

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only